Abstract
SUMMARYThis Cochrane review supports existing recommendations for risperidone and advances understanding of the use of valproate in patients with schizophrenia who are agitated or aggressive.DECLARATION OF INTERESTJ.C. conducted clinical trials of antipsychotics sponsored by Janssen Pharmaceuticals between 1978 and 1998 and met Dr Paul Janssen.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
